Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudwaleit

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
Arthritis and Rheumatism|May 2, 2007
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agentsJ Braun, X Baraliakos, J Listing, et al.
Arthritis Care & Research|April 5, 2013
Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional studyA Moltó, S Paternotte, D Comet, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis]U Kiltz, M Rudwaleit, J Sieper, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]U Kiltz, J Sieper, H Kellner, et al.
Rheumatology (Oxford, England)|May 6, 2003
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritisJ Zou, Y Zhang, A Thiel, et al.
Arthritis and Rheumatism|April 11, 2003
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring systemJ Braun, X Baraliakos, W Golder, et al.
Arthritis and Rheumatism|September 29, 1998
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case reportM Rudwaleit, F Elias, T Humaljoki, et al.
Annals of the Rheumatic Diseases|May 21, 2013
Autoantibodies against CD74 in spondyloarthritisN T Baerlecken, S Nothdorft, G H Stummvoll, et al.
Annals of the Rheumatic Diseases|May 23, 2013
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1J Sieper, J Lenaerts, J Wollenhaupt, et al.
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
Arthritis and Rheumatism|May 2, 2007
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agentsJ Braun, X Baraliakos, J Listing, et al.
Arthritis Care & Research|April 5, 2013
Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional studyA Moltó, S Paternotte, D Comet, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis]U Kiltz, M Rudwaleit, J Sieper, et al.
Zeitschrift Fur Rheumatologie|September 4, 2014
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]U Kiltz, J Sieper, H Kellner, et al.
Rheumatology (Oxford, England)|May 6, 2003
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritisJ Zou, Y Zhang, A Thiel, et al.
Arthritis and Rheumatism|April 11, 2003
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring systemJ Braun, X Baraliakos, W Golder, et al.
Arthritis and Rheumatism|September 29, 1998
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case reportM Rudwaleit, F Elias, T Humaljoki, et al.
Annals of the Rheumatic Diseases|May 21, 2013
Autoantibodies against CD74 in spondyloarthritisN T Baerlecken, S Nothdorft, G H Stummvoll, et al.
Annals of the Rheumatic Diseases|May 23, 2013
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1J Sieper, J Lenaerts, J Wollenhaupt, et al.
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Pageof 14